A recent meta-analysis reports a reduction in the plasma inflammatory biomarkers, C-reactive protein, IL-6, and TNF-α, after CoQ10 supplementation (60 to 500 mg/day, formulations described as CoQ10 or ubiquinol), for 1 week to 4 months in different inflammatory disorders (cardio and cerebral vascular disease, multiple sclerosis, obesity, renal failure, rheumatoid arthritis, diabetes, and fatty liver disease). This evidence concerns the gene CRP and obesity due to melanocortin 4 receptor deficiency.